All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Nurse-led PROM assessment in patients with MPN
Results from an observational study investigating symptom burden and quality of life (QoL) in 102 adults with myeloproliferative neoplasms (MPN) through structured patient-reported outcome measure (PROM)-based nurse-led visits were published in Nursing Open by Berardinelli et al.
Key data: Overall, 60% of patients had essential thrombocythemia (ET), 20% had myelofibrosis (MF), and 20% had polycythemia vera (PV). Symptom burden was substantial across all MPN subtypes, with 85% reporting symptoms and a median MPN-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) of 14.5. Fatigue was the most prevalent symptom (72%), followed by abdominal discomfort (40.2%), cognitive issues (37.2%), early satiety (35.3%), and bone pain (35.3%). Patients with PV vs ET and MF had higher symptom scores (median TSS, 21 vs 12 and 14.5, respectively). Females reported a higher TSS vs males (19 vs 10). Mean global health-related QoL score was 70.7 ± 21.3. Moderate-to-severe fatigue was significantly associated with impaired global health (odds ratio [OR], 4.7; 95% confidence interval [CI], 2.1–11.4; p < 0.001) and clinical depression (OR, 10.5; 95% CI, 1.9–196.3; p = 0.027). Patient satisfaction with the nurse-led visit was high, with a mean score of 9.3 ± 1.3 out of 10.
Key learning: In this study, structured PROM-based nurse-led visits identified multidimensional unmet needs, including physical symptoms, psychological distress, and low patient activation, supporting their integration into routine hematology outpatient care in patients with MPN.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Among patients with myelofibrosis and isolated anemia at presentation, with no indication for treatment with a JAK inhibitor, how often do you use anemia-directed treatments (EMAs, ESAs, danazol, etc.) as monotherapy?
